Senti Biosciences (SNTI) investor relations material

Company overview and business model

• Clinical-stage biotechnology company developing next-generation cell and gene therapies using proprietary gene circuit platform technologies for incurable diseases.

• Focus on engineering CAR-NK cells to target cancer, aiming for high specificity and control over therapeutic effects.

• Mission centers on creating smarter medicines that can sense, compute, and respond to complex disease environments.

Financial performance and metrics

• As of March 31, 2026, net tangible book value was $(10.0) million, or $(0.32) per share, with 31,144,754 shares outstanding.

• After the offering, pro forma net tangible book value would be $(0.6) million, or $(0.01) per share, with immediate dilution of $0.64 per share to new investors.

• Company has incurred recurring losses, negative cash flows, and has an accumulated deficit, raising substantial doubt about its ability to continue as a going concern.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by the selling securityholder; received approximately $9.7 million in net proceeds from the issuance of convertible notes.